Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
306
mi
from 43215
Winston-Salem, NC
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
306
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
130
mi
from 43215
Beachwood, OH
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
130
mi
from 43215
Beachwood, OH
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
6
mi
from 43215
Columbus, OH
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
6
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
8
mi
from 43215
Gahanna, OH
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
8
mi
from 43215
Gahanna, OH
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
133
mi
from 43215
South Euclid, OH
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
133
mi
from 43215
South Euclid, OH
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
162
mi
from 43215
Pittsburgh, PA
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
162
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
524
mi
from 43215
Mt. Pleasant, SC
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
524
mi
from 43215
Mt. Pleasant, SC
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
1517
mi
from 43215
West Jordan, UT
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
1517
mi
from 43215
West Jordan, UT
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
422
mi
from 43215
Norfolk, VA
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
422
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
251
mi
from 43215
Roanoke, VA
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
251
mi
from 43215
Roanoke, VA
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers
A Phase 1, Open-Label, Randomized, Controlled, Four-Period Crossover Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers
Status: Enrolling
Updated:  7/27/2015
GSK Investigational Site
343
mi
from 43215
Baltimore, MD
A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers
A Phase 1, Open-Label, Randomized, Controlled, Four-Period Crossover Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers
Status: Enrolling
Updated: 7/27/2015
GSK Investigational Site
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigator Site
495
mi
from 43215
Birmingham, AL
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigator Site
495
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
627
mi
from 43215
Little Rock, AR
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
627
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
1965
mi
from 43215
Pasadena, CA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
1965
mi
from 43215
Pasadena, CA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
1947
mi
from 43215
San Diego, CA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
1947
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
465
mi
from 43215
Newnan, GA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
465
mi
from 43215
Newnan, GA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
425
mi
from 43215
Snellville, GA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
425
mi
from 43215
Snellville, GA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
276
mi
from 43215
Champaign, IL
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
276
mi
from 43215
Champaign, IL
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigational Site
350
mi
from 43215
Springfield, IL
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigational Site
350
mi
from 43215
Springfield, IL
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigator Site
280
mi
from 43215
Evansville, IN
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigator Site
280
mi
from 43215
Evansville, IN
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigator Site
678
mi
from 43215
Topeka, KA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigator Site
678
mi
from 43215
Topeka, KA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
188
mi
from 43215
Louisville, KY
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative site
643
mi
from 43215
Boston, MA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative site
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from 43215
Clinton Twp., MI
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from 43215
Clinton Twp., MI
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
165
mi
from 43215
Detroit, MI
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
165
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigator Site
625
mi
from 43215
Minneapolis, MN
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigator Site
625
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
397
mi
from 43215
St. Louis, MO
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
397
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
691
mi
from 43215
Omaha, NE
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
691
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
1754
mi
from 43215
Henderson, NV
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
1754
mi
from 43215
Henderson, NV
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis
481
mi
from 43215
New York, NY
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
356
mi
from 43215
Rochester, NY
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
356
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
321
mi
from 43215
High Point, NC
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
321
mi
from 43215
High Point, NC
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigational Site
2026
mi
from 43215
Lake Oswego, OR
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigational Site
2026
mi
from 43215
Lake Oswego, OR
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis
2028
mi
from 43215
Portland, OR
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis
2028
mi
from 43215
Portland, OR
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
416
mi
from 43215
Philadelphia, PA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigational Site
1065
mi
from 43215
Austin, TX
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigational Site
1065
mi
from 43215
Austin, TX
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative site
914
mi
from 43215
Dallas, TX
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative site
914
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
276
mi
from 43215
Charlottesville, VA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
276
mi
from 43215
Charlottesville, VA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
273
mi
from 43215
Lynchburg, VA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
273
mi
from 43215
Lynchburg, VA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from 43215
Nice,
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from 43215
Nice,
Click here to add this to my saved trials
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated:  8/6/2015
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated: 8/6/2015
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated:  8/6/2015
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated: 8/6/2015
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated:  8/6/2015
Clinical Research Facility
394
mi
from 43215
St Louis, MO
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated: 8/6/2015
Clinical Research Facility
394
mi
from 43215
St Louis, MO
Click here to add this to my saved trials
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated:  8/6/2015
Clinical Research Facility
991
mi
from 43215
Houston, TX
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated: 8/6/2015
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials